Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines - PubMed (original) (raw)
Affiliations
- PMID: 9167187
Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines
O Nakanishi et al. Oncol Res. 1997.
Abstract
A novel quinoline compound, MS-209, was examined for its ability to reverse multidrug resistance (MDR) in several murine and human MDR solid tumor cell lines both in vitro and in vivo. MS-209 strongly reversed drug resistance to adriamycin (ADM) and vincristine (VCR) in acquired MDR tumor cell lines, 2780AD and KB-C1. In addition, MS-209 enhanced the cytotoxic effect of ADM and VCR on various human and murine cell lines. Particularly in 4-1St cells, which are extremely resistant to ADM and VCR, MS-209 at a concentration of 3 microM enhanced the cytotoxicity of ADM and VCR, 88- and 350-fold, respectively. MS-209 administered orally, together with ADM, enhanced the antitumor activity of ADM on Colon 26 and 4-1St tumors implanted subcutaneously (SC) in mice; the antitumor effect of ADM plus MS-209 was higher than that of ADM alone at the maximum tolerated dose (MTD). Furthermore, the coadministration schedules of MS-209 to attain the highest potentiation of ADM activity were examined using Colon 26 tumors. The maximum antitumor activity was obtained when MS-209 was administered on the same day as ADM. MS-209 administered a day before the ADM injection exhibited no potentiation effect, whereas MS-209 administered a day after the ADM injection showed a moderate effect. The effect of MS-209 was weaker when administered in a fractionated manner than when administered as a single dose. The results presented in this article suggest that MS-209 is an effective agent to overcome MDR in cancer chemotherapy.
Similar articles
- Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G. Gourdeau H, et al. Cancer Chemother Pharmacol. 2002 Dec;50(6):490-6. doi: 10.1007/s00280-002-0530-7. Epub 2002 Oct 16. Cancer Chemother Pharmacol. 2002. PMID: 12451476 - MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T. Naito M, et al. Clin Cancer Res. 2002 Feb;8(2):582-8. Clin Cancer Res. 2002. PMID: 11839680 - [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
Naito M, Nakanishi O, Tsuruo T. Naito M, et al. Nihon Rinsho. 1997 May;55(5):1122-7. Nihon Rinsho. 1997. PMID: 9155163 Review. Japanese. - In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Nadal JC, Van Groeningen CJ, Pinedo HM, Peters GJ. Nadal JC, et al. Biomed Pharmacother. 1988;42(6):387-93. Biomed Pharmacother. 1988. PMID: 3064823 Review.
Cited by
- Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance.
Cho Y, Kim YK. Cho Y, et al. Front Oncol. 2020 Jun 2;10:764. doi: 10.3389/fonc.2020.00764. eCollection 2020. Front Oncol. 2020. PMID: 32582535 Free PMC article. Review. - P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. Katayama R, et al. EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan. EBioMedicine. 2015. PMID: 26870817 Free PMC article. - A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Nokihara H, Yano S, Nishioka Y, Hanibuchi M, Higasida T, Tsuruo T, Sone S. Nokihara H, et al. Jpn J Cancer Res. 2001 Jul;92(7):785-92. doi: 10.1111/j.1349-7006.2001.tb01162.x. Jpn J Cancer Res. 2001. PMID: 11473730 Free PMC article. - A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. Saito A, et al. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7. doi: 10.1073/pnas.96.8.4592. Proc Natl Acad Sci U S A. 1999. PMID: 10200307 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources